alectinib + crizotinib

Alectinib + crizotinib is a combination of two small molecule tyrosine kinase inhibitors used in the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Crizotinib was the first-in-class ALK inhibitor targeting ALK, ROS1, and MET kinases and is approved for metastatic ALK-positive NSCLC. Alectinib is a second-generation ALK inhibitor that selectively inhibits ALK and RET kinases with greater potency and CNS penetration than crizotinib. The combination targets the ALK fusion protein driving tumor growth in NSCLC patients harboring this mutation. Alectinib has shown superior progression-free survival (PFS), lower toxicity, and better central nervous system (CNS) activity compared to crizotinib when used as first-line therapy. Crizotinib resistance often develops, making sequential or combined use with alectinib relevant in clinical practice.

Other names

alectinib + crizotinib